Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest ViiV Healthcare Stories

2014-04-01 16:25:28

Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare to increase access to dolutegravir (DTG), a promising new antiretroviral (ARV) medication. This agreement will allow generic manufacturers to scale up production of...

2014-04-01 16:25:22

GENEVA, April 1, 2014 /PRNewswire/ -- Access to dolutegravir could improve millions of lives in developing countries The Medicines Patent Pool (MPP) and ViiV Healthcare announced a new collaboration on HIV medicines today, signing two licensing agreements to increase access to dolutegravir (DTG), a promising new antiretroviral, for both adult and paediatric care. The agreements would allow generic...

2014-04-01 16:25:15

- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/ -- ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug...

2014-02-03 23:02:45

Insightful research report “HIV - KOL Insight and Consensus Outlook Modules” worked out by FirstWord has been recently published by Market Publishers Ltd. According to the study, the HIV therapies market is forecast to maintain stable growth in upcoming years. London, UK (PRWEB) February 03, 2014 During 2007-2012, the HIV therapies market registered a CAGR of 12%; however, keeping the growth pace at a high level will be a key challenge in the upcoming years. Currently, the HIV market...

2013-12-18 12:25:41

MUMBAI and BALTIMORE, December 18, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary Lupin Pharmaceuticals Inc. has launched its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg in the US after the US District Court for the District of Delaware ruled that the Lupin's generic version of Trizivir(R) did not infringe on patents. Lupin had earlier received approval for the same. Lupin's...

2013-11-22 08:23:50

LONDON, Nov. 22, 2013 /PRNewswire/ -- ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Tivicay(®) (dolutegravir) for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age. "We welcome the CHMP's positive opinion on dolutegravir - it puts us a step...

2013-10-22 12:29:36

LONDON, Oct. 22, 2013 /PRNewswire/ -- ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug Application (NDA) follows the approval of dolutegravir by the US Food and Drug Administration (FDA) in August 2013 under the brand name Tivicay(®), approved for use in combination with other...

2013-09-12 20:21:33

DENVER, Sept. 12, 2013 /PRNewswire/ -- ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time, compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) (800mg darunavir boosted with 100mg ritonavir) in treatment-naive adults with HIV-1. Both treatment arms were administered with investigator-selected dual NRTIs. Non-inferiority was demonstrated...

2013-09-04 08:32:36

Positive Action Southern Initiative Expands into Two Additional States and Renews Funding for Current Network Organizations, Bringing Total Funding for Grassroots Projects to More than 2.3 Million to Date RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2013 /PRNewswire/ -- ViiV Healthcare announced today the first Positive Action Southern Initiative (PASI) grant awardees in Texas and Virginia and seven grant awards to current network members in Florida, North Carolina, South Carolina, and Tennessee....

2013-08-13 00:20:51

LONDON, Aug. 12, 2013 /PRNewswire/ -- ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay(®) (dolutegravir) 50-mg tablets. Tivicay is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg (approx. 88 lbs). To view the multimedia assets associated with this release, please click:...